A study of XW003 for obesity with sleep apnea (no CPAP)
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your BMI must be 28 or higher.
- You must have moderate to severe sleep apnea (AHI ≥15) confirmed by a sleep study.
- You cannot have used a CPAP or other breathing machine for at least 4 weeks before the study, and you agree not to use one during the study.
- You must have tried to lose weight by dieting at least once but it didn't work well enough.
- You cannot have diabetes (except gestational diabetes in the past).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called XW003 to see if it helps people with obesity and obstructive sleep apnea who are already using a positive airway pressure (PAP) machine, like CPAP. It aims to improve weight loss and sleep apnea symptoms.
This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.
This study tests an investigational medicine given as an injection to help people with obstructive sleep apnea and a high body mass index (BMI). It may reduce breathing pauses during sleep and support weight loss, all while you continue using your CPAP machine.
This study tests a new injectable medicine (NNC0487-0111) to help people lose weight and improve obstructive sleep apnea (a breathing condition during sleep). You must already be using a CPAP machine (positive airway pressure device) for your sleep apnea.
This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.
This study tests a new injection (MWN117) in healthy people and in people with obesity. It aims to see if the drug is safe and how the body handles it, which may eventually help with weight management.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.